Johnson & Johnson’s pursuit of bankruptcy protection for its subsidiary to handle billions in cancer claims linked to its baby powder has twice been thwarted in New Jersey courts. The pharmaceutical giant is now targeting Texas for its third attempt, leveraging the state’s reputation for more business-friendly judicial environments (Bloomberg Law).
Following rejected bids in New Jersey, where judges determined the financial distress claimed by J&J’s unit was insufficient for bankruptcy protection, the company has outlined plans to pursue a Chapter 11 filing in Texas, complete with a proposed $6.5 billion settlement offer for claimants. This strategic forum shopping is aiming to position the case in a jurisdiction thought to potentially favor corporate interests.
“It’s a blatant case of forum shopping,” said Robert Lawless, a law professor at the University of Illinois. This move, known as the Texas Two Step, involves the company isolating its liabilities in a specific unit to contain the litigation risks.
Last year, J&J shifted the location of the concerned unit to Texas, setting the stage for this third attempt. Despite past resistance in other jurisdictions, J&J remains resolute in its stance that their talc-based powders have not caused cancer and that it has responsibly marketed these products over a century. The unit’s prior bids for bankruptcy protection were quashed, partly because J&J’s substantial financial backing diminished the perceived financial distress.
Moreover, the move to Texas follows a broader trend, as highlighted by other high-profile relocations such as Tesla. The shift underscores the ongoing debate about the fairness of methods like the Texas Two Step, which some critics argue allows solvent companies to offload mass tort liabilities in bankruptcy courts, often leading to less favorable outcomes for claimants.
For this new attempt, J&J has reportedly gained the support of over 75% of the claimants, a critical threshold that could enable a swift approval of the settlement plan by the bankruptcy judge. This plan offers a $6.5 billion resolution for pending and future cancer claims linked to its talc products.
Legal analysts remain divided on the strategy’s potential success. Melissa Jacoby of the University of North Carolina suggests that the prospects of success should be minimal. In contrast, Samir Parikh from Wake Forest University sees the possibility of the process delivering a fair compensation to victims who have awaited justice for years.
This case highlights a continuing legal dilemma and sets the stage for complex judicial debates over corporate bankruptcy tactics and their broader implications on mass tort litigation.